Alphatec Holdings, Inc. (“ATEC,” or the “Company”) (Nasdaq: ATEC),
a provider of innovative spine surgery solutions with a mission to
improve patient lives through the relentless pursuit of superior
outcomes, today reported financial results for the third quarter
ended September 30, 2018 and corporate highlights.
Third Quarter 2018 Financial
Highlights
- Total net revenue of $23.0 million; U.S. commercial revenue of
$21.0 million, up 3% compared to the second quarter of 2018
- U.S. commercial gross margin of 70.1%
- Cash and cash equivalents of $35.1 million at September 30,
2018
- Operating cash burn (excluding debt service and
transaction-related costs) of $6.4 million
Organizational, Commercial and Product
Highlights
- Completed a $35 million debt financing and retired the
Company’s $29.2 million term loan with Globus Medical, Inc., which
will reduce debt service costs by approximately $27 million over
the next three years
- Obtained 510(k) clearance for the
OsseoScrew® System, the first-of-its-kind, expandable
pedicle screw system, intended to restore the integrity of the
spinal column in patients with advanced stage tumors involving the
thoracic and lumbar spine
- Continued transition of the sales organization and increased
contribution from dedicated agents to 63% of U.S. commercial
revenue
- Made three key additions to the ATEC leadership team: Mark
Ojeda, Executive Vice President of Cervical & Biologics, and
Darrell Wilson and Mason Zabel, Territory Development Managers for
the Central United States, who collectively bring decades of spine
industry success to ATEC
“I am exceptionally proud of our accomplishments
in the third quarter,” said Pat Miles, Chairman and Chief Executive
Officer of ATEC. “We achieved another quarter of sequential growth
in U.S. commercial revenue, in what is traditionally a seasonally
challenging quarter for spine. We also experienced year-over-year
revenue growth in our U.S. commercial business for the first time
since we began the process of reducing non-strategic distributor
relationships in early 2017. We are building a motivated and
focused sales force while bringing clinical distinction to our
portfolio in order to accelerate new surgeon adoption. The surgeons
and sales representatives who now are partnering with us recognize
that change is coming and believe wholeheartedly in the ability of
this team to bring profound innovation to a market that needs
it.”
Comparison of Financial Results for the Third Quarter
2018 to Second Quarter 2018
The following table compares key third quarter
2018 results to second quarter 2018 results.
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Change |
|
September 30, 2018 |
|
June 30, 2018 |
|
$ |
|
% |
|
(unaudited) |
|
(unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
U.S. commercial
revenue |
$ |
20,996 |
|
|
$ |
20,409 |
|
|
$ |
587 |
|
|
3 |
% |
U.S. gross profit |
|
14,709 |
|
|
|
14,178 |
|
|
|
531 |
|
|
4 |
% |
U.S. gross margin |
|
70.1 |
% |
|
|
69.5 |
% |
|
|
|
|
|
|
|
|
|
|
|
|
Operating Expenses |
|
|
|
|
|
|
|
Research
and development |
$ |
3,157 |
|
|
$ |
2,009 |
|
|
$ |
1,148 |
|
|
57 |
% |
Sales and
marketing |
|
10,956 |
|
|
|
10,673 |
|
|
|
283 |
|
|
3 |
% |
General
and administrative |
|
7,914 |
|
|
|
7,815 |
|
|
|
99 |
|
|
1 |
% |
Amortization of intangible assets |
|
187 |
|
|
|
187 |
|
|
|
- |
|
|
0 |
% |
Transaction-related expenses |
|
66 |
|
|
|
(62 |
) |
|
|
128 |
|
|
(206 |
%) |
Restructuring |
|
167 |
|
|
|
193 |
|
|
|
(26 |
) |
|
(13 |
%) |
Total
operating expenses |
$ |
22,447 |
|
|
$ |
20,815 |
|
|
$ |
1,632 |
|
|
8 |
% |
|
|
|
|
|
|
|
|
Operating loss |
$ |
(7,533 |
) |
|
$ |
(6,545 |
) |
|
$ |
(988 |
) |
|
15 |
% |
|
|
|
|
|
|
|
|
Interest and other
expense |
$ |
(1,754 |
) |
|
$ |
(1,784 |
) |
|
$ |
30 |
|
|
(2 |
%) |
|
|
|
|
|
|
|
|
Loss from continuing
operations |
$ |
(9,313 |
) |
|
$ |
(7,064 |
) |
|
$ |
(2,249 |
) |
|
32 |
% |
|
|
|
|
|
|
|
|
Non-GAAP Adjusted
EBITDA |
$ |
(3,401 |
) |
|
$ |
(3,577 |
) |
|
$ |
176 |
|
|
(5 |
%) |
|
|
|
|
|
|
|
|
U.S. commercial revenue for the third quarter of
2018 was $21.0 million, compared to $20.4 million in the second
quarter of 2018. Revenue growth generated by the expansion of the
dedicated sales channel, coupled with new surgeon adoption, offset
the revenue losses associated with the intentional reduction of
non-strategic distributor relationships.
U.S. gross profit and gross margin for the third
quarter of 2018 were $14.7 million and 70.1%, respectively,
compared to $14.2 million and 69.5% for the second quarter of 2018.
U.S. gross margin stabilized as the Company continued to reduce
product costs and optimize its supply chain.
Total operating expenses for the third quarter
of 2018 were $22.4 million, compared to $20.8 million in the second
quarter of 2018. On a non-GAAP basis (excluding stock-based
compensation, the SafeOp contingent consideration fair-value
adjustment, restructuring charges, and transaction-related
expenses), total operating expenses in the third quarter increased
to $20.0 million, compared to $19.4 million in the second quarter
of 2018. The increase in total operating expenses is primarily the
result of growth-related investments into research and development
and sales.
GAAP loss from continuing operations for the
third quarter of 2018 was $9.3 million, compared to a loss of $7.1
million for the second quarter of 2018. The increased loss is
primarily the result of higher operating expenses attributable to
growth-related investments into research and development, the
SafeOp contingent consideration fair-value adjustment, and an
increase in stock-based compensation expense.
Non-GAAP Adjusted EBITDA for the third quarter
of 2018 was $(3.4) million, compared to $(3.6) million in the
second quarter of 2018. For more detailed information, please refer
to the table, “Alphatec Holdings, Inc. Reconciliation of Non-GAAP
Financial Measures,” that follows.
Current and long-term debt includes $29.2
million in term debt and $9.5 million outstanding under the
Company’s revolving credit facility at September 30, 2018. This
compares to $30.6 million in term debt and $8.2 million outstanding
under the Company’s revolving credit facility at June 30, 2018.
Cash and cash equivalents were $35.1 million at
September 30, 2018, compared to $44.9 million at June 30,
2018.
Comparison of Financial Results for the
Three and Nine Months Ended September 30, 2018 and
2017
On a year-over-year basis, revenue has been
impacted by the ongoing transition of the Company’s distribution
channel to more dedicated, scalable partners and the
discontinuation of non-strategic distributor relationships. The
effectiveness of the dedicated sales channel, coupled with new
surgeon adoption, is beginning to offset revenue losses associated
with the transition. The year-over-year increase in operating
expenses is attributable to litigation support costs,
transaction-related expenses associated with the Company’s
acquisition of SafeOp Surgical, Inc., and increased investment in
product development initiatives as the Company expands its product
pipeline. For additional information, please reference the
financial statement tables that follow and the Company’s Quarterly
Report on Form 10-Q to be filed with the Securities and Exchange
Commission on or before November 9, 2018.
2018 Financial Outlook
With improved clarity into how the remainder of
the year will progress, ATEC now expects total revenue for 2018 in
the range of $92 to $95 million, compared to the Company’s previous
revenue guidance of approximately $95 million. This guidance
reflects anticipated fourth quarter domestic revenue growth of more
than 10%, on both a sequential and year-over-year basis.
Refinanced Debt Facility
On November 6, 2018, ATEC closed $35 million in
senior secured debt financing from Squadron Medical Finance
Solutions, a provider of debt financing to growing companies in the
orthopedic industry. Net proceeds of approximately $33.8
million, after estimated expenses, were used to retire the
Company’s existing $29.2 million term debt. The remainder of
the proceeds will be used for general corporate purposes.
The debt has a five-year maturity and bears
interest at LIBOR plus 8% (currently 10.3%) per year. Interest-only
payments are due monthly through May 2021, followed by $10 million
in principal payable in 29 equal monthly installments beginning
June 2021, and a $25 million lump-sum payment at maturity
in November 2023.
This new term loan reduces the Company’s cost of
debt capital by approximately 5% and extends amortization by an
additional 30 months over the prior term loan. The new term loan
decreases debt service cash requirements by nearly $27 million over
the next three years, significantly enhancing the Company’s
flexibility during a critical time for growth-related
investments.
In connection with the financing, ATEC issued
warrants to Squadron to purchase 845,000 shares of common stock at
an exercise price of $3.15 per share. The warrants
have a seven-year term and are exercisable immediately.
Investor Conference Call
ATEC will hold a conference call today at 1:30
p.m. PT / 4:30 p.m. ET to discuss its third quarter 2018 results.
The dial-in numbers are (877) 556-5251 for domestic callers and
(720) 545-0036 for international callers. The conference ID number
is 8275528. A live webcast of the conference call will also be
available online from the Investor Relations page of the Company's
corporate website at www.atecspine.com.
A replay of the webcast will remain available on
the Company’s website until November 8, 2019. In addition, a
telephonic replay of the call will be available until November 15,
2018. The replay dial-in numbers are (855) 859-2056 for domestic
callers and (404) 537-3406 for international callers. Please use
the replay conference ID number 8275528.
About Alphatec Holdings,
Inc.
Alphatec Holdings, Inc., through its wholly
owned subsidiaries, Alphatec Spine, Inc. and SafeOp Surgical, Inc.,
is a medical device company that designs, develops, and markets
technology for the treatment of spinal disorders associated with
disease and degeneration, congenital deformities, and trauma. The
Company's mission is to improve lives by providing innovative spine
surgery solutions through the relentless pursuit of superior
outcomes. The Company markets its products in the U.S. via
independent sales agents and a direct sales force.
Additional information can be found at
www.atecspine.com.
About Squadron Medical Finance
Solutions, LLC, a division of Squadron Capital
Squadron Capital seeks to acquire and invest in
operating companies located both in the US and abroad. The
Company’s mission is long-term investment (multi-generational) and
assistance to the portfolio companies’ leadership teams in the
execution of their business plans. Squadron Medical Finance
Solutions assists orthopedic OEMs in achieving their business
objectives by offering financing of surgical instruments and
implant sets, or by providing debt financing to support the broader
capital requirements of growing companies.
Non-GAAP Financial
Information
To supplement the Company’s financial statements
presented in accordance with U.S. generally accepted accounting
principles (GAAP), the Company reports certain non-GAAP financial
measures such as Adjusted EBITDA. Adjusted EBITDA included in
this press release is a non-GAAP financial measure that represents
net income (loss), excluding the effects of interest, taxes,
depreciation, amortization, stock-based compensation expenses, and
other non-recurring income or expense items, such as sale of
assets, settlement gains, impairments, restructuring expenses,
severance expenses, fair market value adjustments, and
transaction-related expenses. The Company believes that non-GAAP
Adjusted EBITDA provides investors with an additional tool for
evaluating the Company's core performance, which management uses in
its own evaluation of continuing operating performance, and a
baseline for assessing the future earnings potential of the
Company. For completeness, management uses non-GAAP Adjusted
EBITDA in conjunction with GAAP earnings and earnings per common
share measures. The Company’s Adjusted EBITDA measure may not
provide information that is directly comparable to that provided by
other companies in the Company’s industry, as other companies in
the industry may calculate non-GAAP financial results differently,
particularly related to non-recurring, unusual items. Adjusted
EBITDA should be considered in addition to, and not as a substitute
for, or superior to, financial measures calculated in accordance
with GAAP. Included below are reconciliations of the non-GAAP
financial measures to the comparable GAAP financial measure.
Forward-Looking Statements
This press release contains "forward-looking
statements" within the meaning of the Private Securities Litigation
Reform Act of 1995 that involve risks and uncertainty. Such
statements are based on management's current expectations and are
subject to a number of risks and uncertainties that could cause
actual results to differ materially from those described in the
forward-looking statements. The Company cautions investors that
there can be no assurance that actual results or business
conditions will not differ materially from those projected or
suggested in such forward-looking statements as a result of various
factors. Forward-looking statements include the references to the
Company’s strategy in significantly repositioning the ATEC brand
and turning the Company into a growth organization. The
important factors that could cause actual operating results to
differ significantly from those expressed or implied by such
forward-looking statements include, but are not limited to: the
uncertainty of success in developing new products or products
currently in the Company’s pipeline; the uncertainties in the
Company’s ability to execute upon its strategic operating plan; the
uncertainties regarding the ability to successfully license or
acquire new products, and the commercial success of such products;
failure to achieve acceptance of the Company’s products by the
surgeon community; failure to obtain FDA or other regulatory
clearance or approval for new products, or unexpected or prolonged
delays in the process; continuation of favorable third party
reimbursement for procedures performed using the Company’s
products; unanticipated expenses or liabilities or other adverse
events affecting cash flow or the Company’s ability to successfully
control its costs or achieve profitability; uncertainty of
additional funding; uncertainties associated with the anticipated
cash savings from the Squadron debt financing over the next three
years; the Company’s ability to compete with other competing
products and with emerging new technologies; product liability
exposure; an unsuccessful outcome in any litigation in which the
Company is a defendant; patent infringement claims; claims related
to the Company’s intellectual property and the Company’s ability to
meet its financial obligations under its credit agreements and the
OrthoTec LLC settlement agreement. The words “believe,” “will,”
“should,” “expect,” “intend,” “estimate” and “anticipate,”
variations of such words and similar expressions identify
forward-looking statements, but their absence does not mean that a
statement is not a forward-looking statement. A further list
and description of these and other factors, risks and uncertainties
can be found in the Company's most recent annual report, and any
subsequent quarterly and current reports, filed with
the Securities and Exchange Commission. ATEC disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events,
or otherwise, unless required by law.
Investor/Media Contact:Tina
JacobsenInvestor Relationsir@atecspine.com
Company Contact:Jeff BlackExecutive Vice
President and Chief Financial OfficerAlphatec Holdings,
Inc.ir@atecspine.com
|
|
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED STATEMENTS OF
OPERATIONS |
(in thousands, except per share amounts -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
September 30, |
|
September 30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenues |
$ |
23,002 |
|
|
$ |
23,099 |
|
|
$ |
66,351 |
|
|
$ |
75,456 |
|
Cost of revenues |
|
8,088 |
|
|
|
8,587 |
|
|
|
23,597 |
|
|
|
28,417 |
|
Gross profit |
|
14,914 |
|
|
|
14,512 |
|
|
|
42,754 |
|
|
|
47,039 |
|
|
|
|
|
|
|
|
|
Operating
expenses: |
|
|
|
|
|
|
|
Research
and development |
|
3,157 |
|
|
|
1,044 |
|
|
|
6,952 |
|
|
|
3,483 |
|
Sales and
marketing |
|
10,956 |
|
|
|
10,015 |
|
|
|
31,689 |
|
|
|
31,416 |
|
General
and administrative |
|
7,914 |
|
|
|
4,403 |
|
|
|
22,171 |
|
|
|
15,977 |
|
Amortization of intangible assets |
|
187 |
|
|
|
172 |
|
|
|
551 |
|
|
|
516 |
|
Transaction-related expenses |
|
66 |
|
|
|
- |
|
|
|
1,546 |
|
|
|
- |
|
Gain on
settlement |
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
|
|
- |
|
Restructuring expenses |
|
167 |
|
|
|
139 |
|
|
|
758 |
|
|
|
1,898 |
|
Gain on
sale of assets |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(856 |
) |
Total operating
expenses |
|
22,447 |
|
|
|
15,773 |
|
|
|
57,499 |
|
|
|
52,434 |
|
Operating loss |
|
(7,533 |
) |
|
|
(1,261 |
) |
|
|
(14,745 |
) |
|
|
(5,395 |
) |
Other income
(expense): |
|
|
|
|
|
|
|
Interest
expense, net |
|
(1,748 |
) |
|
|
(1,807 |
) |
|
|
(5,164 |
) |
|
|
(5,669 |
) |
Other
income, net |
|
(6 |
) |
|
|
(15 |
) |
|
|
(19 |
) |
|
|
(8 |
) |
Total other expense,
net |
|
(1,754 |
) |
|
|
(1,822 |
) |
|
|
(5,183 |
) |
|
|
(5,677 |
) |
Loss from continuing
operations before taxes |
|
(9,287 |
) |
|
|
(3,083 |
) |
|
|
(19,928 |
) |
|
|
(11,072 |
) |
Income
tax (benefit) provision |
|
26 |
|
|
|
(7 |
) |
|
|
(1,697 |
) |
|
|
57 |
|
Loss from continuing
operations |
|
(9,313 |
) |
|
|
(3,076 |
) |
|
|
(18,231 |
) |
|
|
(11,129 |
) |
Loss from
discontinued operations |
|
(42 |
) |
|
|
(61 |
) |
|
|
(116 |
) |
|
|
(220 |
) |
Net loss |
$ |
(9,355 |
) |
|
$ |
(3,137 |
) |
|
$ |
(18,347 |
) |
|
$ |
(11,349 |
) |
|
|
|
|
|
|
|
|
Net loss per
share, basic and diluted: |
|
|
|
|
|
|
|
Continuing operations |
$ |
(0.22 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.56 |
) |
|
$ |
(0.98 |
) |
Discontinued operations |
|
(0.00 |
) |
|
|
(0.01 |
) |
|
|
(0.00 |
) |
|
|
(0.02 |
) |
Net loss per share,
basic and diluted |
$ |
(0.22 |
) |
|
$ |
(0.23 |
) |
|
$ |
(0.56 |
) |
|
$ |
(1.00 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Shares
used in calculating basic and diluted net loss per share |
|
42,497 |
|
|
|
13,938 |
|
|
|
32,658 |
|
|
|
11,349 |
|
|
|
|
|
|
|
|
|
Stock-based
compensation included in: |
|
|
|
|
|
|
|
Cost of revenue |
|
18 |
|
|
|
13 |
|
|
|
51 |
|
|
|
27 |
|
Research and
development |
|
179 |
|
|
|
(52 |
) |
|
|
192 |
|
|
|
239 |
|
Sales and
marketing |
|
223 |
|
|
|
134 |
|
|
|
527 |
|
|
|
358 |
|
General and
administrative |
|
1,255 |
|
|
|
355 |
|
|
|
2,672 |
|
|
|
1,045 |
|
|
$ |
1,675 |
|
|
$ |
450 |
|
|
$ |
3,442 |
|
|
$ |
1,669 |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
CONDENSED CONSOLIDATED BALANCE
SHEETS |
(in thousands) |
|
|
|
|
|
|
|
|
|
September 30, |
|
December 31, |
|
2018 |
|
2017 |
|
(unaudited) |
|
|
ASSETS |
Current assets: |
|
|
|
Cash and cash
equivalents |
$ |
35,111 |
|
|
$ |
22,466 |
|
Accounts
receivable, net |
|
12,204 |
|
|
|
14,822 |
|
Inventories, net |
|
28,988 |
|
|
|
27,292 |
|
Prepaid
expenses and other current assets |
|
1,530 |
|
|
|
1,767 |
|
Current
assets of discontinued operations |
|
246 |
|
|
|
131 |
|
Total current
assets |
|
78,079 |
|
|
|
66,478 |
|
|
|
|
|
Property and equipment,
net |
|
12,295 |
|
|
|
12,670 |
|
Goodwill |
|
14,469 |
|
|
|
- |
|
Intangibles, net |
|
26,345 |
|
|
|
5,248 |
|
Other assets |
|
223 |
|
|
|
208 |
|
Noncurrent assets of
discontinued operations |
|
54 |
|
|
|
56 |
|
Total assets |
$ |
131,465 |
|
|
$ |
84,660 |
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS' EQUITY
(DEFICIT) |
Current
liabilities: |
|
|
|
Accounts
payable |
$ |
5,642 |
|
|
$ |
3,878 |
|
Accrued
expenses |
|
20,897 |
|
|
|
22,246 |
|
Current
portion of long-term debt |
|
6,186 |
|
|
|
3,306 |
|
Current
liabilities of discontinued operations |
|
419 |
|
|
|
312 |
|
Total current
liabilities |
|
33,144 |
|
|
|
29,742 |
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
long term liabilities |
|
50,505 |
|
|
|
57,973 |
|
Redeemable preferred stock |
|
23,603 |
|
|
|
23,603 |
|
Stockholders' equity |
|
24,213 |
|
|
|
(26,658 |
) |
Total liabilities and
stockholders' deficit |
$ |
131,465 |
|
|
$ |
84,660 |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF NON-GAAP FINANCIAL
MEASURES |
(in thousands -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three MonthsEnded |
|
Three Months Ended |
|
Nine Months Ended |
|
June 30, |
|
September 30, |
|
September 30, |
|
2018 |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating expenses |
$ |
20,815 |
|
|
$ |
22,447 |
|
|
$ |
15,773 |
|
|
$ |
57,499 |
|
|
$ |
52,434 |
|
Adjustments: |
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
(1,137 |
) |
|
|
(1,657 |
) |
|
|
(437 |
) |
|
|
(3,391 |
) |
|
|
(1,642 |
) |
Contingent consideration fair value adjustment |
|
(100 |
) |
|
|
(546 |
) |
|
|
- |
|
|
|
(646 |
) |
|
|
- |
|
Restructuring |
|
(193 |
) |
|
|
(167 |
) |
|
|
(139 |
) |
|
|
(758 |
) |
|
|
(1,898 |
) |
Transaction-related expenses |
|
62 |
|
|
|
(66 |
) |
|
|
- |
|
|
|
(1,546 |
) |
|
|
- |
|
Gain on
settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
6,168 |
|
|
|
- |
|
Gain on
sale of assets |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
856 |
|
Non-GAAP operating
expenses |
$ |
19,447 |
|
|
$ |
20,011 |
|
|
$ |
15,197 |
|
|
$ |
57,326 |
|
|
$ |
49,750 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three MonthsEnded |
|
Three Months Ended |
|
Nine Months Ended |
|
June 30, |
|
September 30, |
|
September 30, |
|
2018 |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
|
|
|
|
|
|
|
|
|
|
Operating loss, as
reported |
$ |
(6,545 |
) |
|
$ |
(7,533 |
) |
|
$ |
(1,261 |
) |
|
$ |
(14,745 |
) |
|
$ |
(5,395 |
) |
Add
back: |
|
|
|
|
|
|
|
|
|
Depreciation |
|
1,457 |
|
|
|
1,491 |
|
|
|
1,564 |
|
|
|
4,454 |
|
|
|
4,834 |
|
Amortization of
intangible assets |
|
132 |
|
|
|
187 |
|
|
|
234 |
|
|
|
612 |
|
|
|
702 |
|
Total EBITDA |
|
(4,956 |
) |
|
|
(5,855 |
) |
|
|
537 |
|
|
|
(9,679 |
) |
|
|
141 |
|
|
|
|
|
|
|
|
|
|
|
Add back significant
items: |
|
|
|
|
|
|
|
|
|
Stock-based compensation |
|
1,148 |
|
|
|
1,675 |
|
|
|
450 |
|
|
|
3,442 |
|
|
|
1,669 |
|
Contingent consideration fair value adjustment |
|
100 |
|
|
|
546 |
|
|
|
- |
|
|
|
646 |
|
|
|
- |
|
Restructuring |
|
193 |
|
|
|
167 |
|
|
|
139 |
|
|
|
758 |
|
|
|
1,898 |
|
Transaction-related expenses |
|
(62 |
) |
|
|
66 |
|
|
|
- |
|
|
|
1,546 |
|
|
|
- |
|
Gain on
settlement |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(6,168 |
) |
|
|
- |
|
Gain on
sale of assets |
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
- |
|
|
|
(856 |
) |
|
|
|
|
|
|
|
|
|
|
Adjusted EBITDA |
$ |
(3,577 |
) |
|
$ |
(3,401 |
) |
|
$ |
1,126 |
|
|
$ |
(9,455 |
) |
|
$ |
2,852 |
|
|
|
|
|
|
ALPHATEC HOLDINGS, INC. |
RECONCILIATION OF GEOGRAPHIC SEGMENT REVENUES
AND GROSS PROFIT |
(in thousands, except percentages -
unaudited) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended |
|
Nine Months Ended |
|
September 30, |
|
September 30, |
|
2018 |
|
2017 |
|
2018 |
|
2017 |
Revenues by source |
|
|
|
|
|
|
|
U.S. commercial
revenue |
$ |
20,996 |
|
|
$ |
20,662 |
|
|
$ |
60,606 |
|
|
$ |
65,976 |
|
Other |
|
2,006 |
|
|
|
2,437 |
|
|
|
5,745 |
|
|
|
9,480 |
|
Total revenues |
$ |
23,002 |
|
|
$ |
23,099 |
|
|
$ |
66,351 |
|
|
$ |
75,456 |
|
|
|
|
|
|
|
|
|
Gross profit by
source |
|
|
|
|
|
|
|
U.S. |
$ |
14,709 |
|
|
$ |
14,280 |
|
|
$ |
42,319 |
|
|
$ |
46,069 |
|
Other |
|
205 |
|
|
|
232 |
|
|
|
435 |
|
|
|
970 |
|
Total gross profit |
$ |
14,914 |
|
|
$ |
14,512 |
|
|
$ |
42,754 |
|
|
$ |
47,039 |
|
|
|
|
|
|
|
|
|
Gross profit margin by
source |
|
|
|
|
|
|
|
U.S. |
|
70.1 |
% |
|
|
69.1 |
% |
|
|
69.8 |
% |
|
|
69.8 |
% |
Other |
|
10.2 |
% |
|
|
9.5 |
% |
|
|
7.6 |
% |
|
|
10.2 |
% |
Total gross profit
margin |
|
64.8 |
% |
|
|
62.8 |
% |
|
|
64.4 |
% |
|
|
62.3 |
% |
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alphatec (NASDAQ:ATEC)
Historical Stock Chart
From Apr 2023 to Apr 2024